zurück

Eptinezumab (new indication: prophylaxis of migraine)

 

Subject:

  • Active Sustance: Eptinezumab
  • Name: Vyepti®
  • Therapeutic area: Prophylaxis of migraine
  • Pharmaceutical company: Lundbeck GmbH

 

Time table:

  • Start: 01.09.2022
  • Publication of assessment: 01.12.2022
  • End of public hearing: 22.12.2022
  • Final decision by G-BA: middle of February 2023

 

Comparative therapy:

  1. Patients, who are eligible for conventional migraine prophylaxis:
    - Metoprolol or propranolol or flunarizine or topiramate or amitriptyline or Clostridium botulinum toxin type A, taking into account the marketing authorization and prior therapy(ies)
  2. Patients, who do not respond to, are not suitable for, or are intolerant of any of the drug therapies/classes of drugs mentioned (metoprolol, propranolol, flunarizine, topiramate, amitriptyline, Clostridium botulinum toxin type A:
    - Erenumab or fremanezumab or galcanezumab